Mechanisms and management of amphotericin B-induced nephrotoxicity

Cancer Practice

Volumn 5, Issue 3, 1997, Pages 176-181

  Miano Mason, Tina M ^a  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANTIBIOTIC THERAPY; ARTICLE; CANCER PATIENT; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; MYCOSIS; NEPHROTOXICITY;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; DRUG MONITORING; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY DISEASES; NURSING ASSESSMENT; PATIENT CARE PLANNING;

EID: 0030917865     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Anonymous. Fungal infections: deadly in the immunocompromised. Emerg Med 1989; 21:18-20,22-23,26.
2. Marzouk JB, Kennedy CD. Practical guidelines for managing superficial and invasive infections. Consultant 1992; 32:71-74,77-78.
3. Stein RS, Greer JP, Ferrin W, Lenox R, Baer, MR, Flexnor JM. Clinical experience with amphotericin B in acute myelogenous leukemia. South Med J 1986; 79:863-870.
4. Markman M. Common complications and emergencies associated with cancer and its therapy. Cleve Clin J Med 1994; 61:105-114.
5. Sugar AM. Empiric treatment of fungal infections in the neutropenic host. Arch Int Med 1990; 150:2258-2264.
6. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101-111.
7. Robertson MJ, Larson RA. Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med 1988; 84:233-239.
8. Sarosi GA. Amphotericin B: still the 'gold standard' for antifungal therapy. Postgrad Med 1990; 88:151-166.
9. Benedict S, Colagreco J. Fungal infections associated with malignancies, treatments, and AIDS. Cancer Nurs 1994; 17:411-417.
10. Bennett JE. Antimicrobial agents: antifungal agents. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990:1165-1168.
11. Hay RJ. Antifungal drugs on the horizon. J Am Acad Dermatol 1994; 31:S82-S86.
12. Carlson MA, Condon RE. Nephrotoxicity of amphtoericin B. J Am Coll Surg 1994; 179:361-381.
13. Janknegt R, de Marie S, Bakker-Woudenberg I, Crommelin D. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 1992; 23:279-291.
14. Legrand P, Vertut-Doi A, Bolard J. Liposomal amphotericin B: bases of therapeutic index increase. Biomater Artif Cells Immobilization Biotechnol 1993; 21:407-413.
15. de Marie S, Janknegt R, Bakker-Woudenberg IA. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33:907-916.
16. Podrasky DL. Amphotericin B: the nurse's role in controlling adverse reactions. Focus Crit Care 1989; 16:194-198.
17. Schmitt H. New methods of delivery of amphotericin B. Clin Infect Dis 1993; 17(suppl 2):501-506.
18. Physician's Desk Reference. 50th ed. Montvale, NJ: Medical Economics; 1996:506-507.
19. Rutledge DN, Holtzclaw BJ. Use of amphotericin B in immunosuppressed patients with cancer: part one, pharmacology and toxicities. Oncol Nurs Forum 1990; 17:731-736.
20. Bodey GP. Topical and systemic agents. Med Clin North Am 1988; 72:637-659.
21. Khoo SH, Bond J, Denning DW. Administering amphotericin B-A practical approach. Br Soc Antimicrob Chemother 1994; 33:203-213.
22. Lyman CA, Walsh TJ. Systemically administered antifungal agents: a review of their clinical pharmacology and therapeutic application. Drugs 1992; 44:9-35.
23. Mathewson HS. Systemic antifungal agents. Respir Care 1990; 35:987-989.
24. Paller MS. Drug-induced nephropathies. Med Clin North Am 1990; 74:909-917.
25. Bennett WM, Porter GA. Nephrotoxicity of common drugs used by urologists. Urol Clin North Am 1990;17:145-146.
26. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-329.
27. Gardner ML, Godley PJ, Wasan SM. Sodium loading treatment for amphotericin B-induced nephrotoxicity. Drug Intelligence Clin Pharm: Ann Pharmacother 1990; 24:940-946.
28. Barriere SL. Pharmacology and pharmacokinetics of traditional systemic antifungal agents. Pharmacotherapy 1990; 10(suppl 6): 134-140.
29. Raymond JR. Amphotericin B nephrotoxicity. Am Fam Physician 1988; 38:199-203.
30. Hoeprich PD. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 1992; 14(suppl 1):114-119.
31. Mahon SM. Taking the terror out of amphotericin B. Am J Nurs 1988; 88:961-965.
32. Schrier RW, Gooschalk CW, eds. Diseases of the Kidney. 6th ed. Vol 3. Boston, MA: Little Brown and Co; 1997.
33. Guyton AC, Hall JE, eds. Textbook of Medical Physiology. 9th ed. Philadelphia, PA: WB Saunders Co; 1996.
34. West JB, ed. Best and Taylor's Physiological Basis of Medical Practice. 12th ed. Baltimore, MD: Williams & Wilkins; 1991.
35. Walsh ML, Johnson CC. Update on antimicrobial agents. Nurs Clin North Am 1991; 26:341-360.
36. Cohen J. Laboratory monitoring of antifungal chemotherapy. Lancet 1991; 337:1577-1580.
37. Rose BD. Clinical Physiology of Acid-Base and Electrolyte Disorders. 4th ed. New York: McGraw-Hill; 1994.
38. Tisher CC. Nephrology for the House Officer. 2nd ed. Baltimore, MD: Williams & Wilkins; 1993.
39. Schrier RW, ed. Renal and Electrolyte Disorders. 3rd ed. Boston, MA: Little Brown and Co; 1986.
40. Kintzel PE, Smith GH. Practical guidelines for preparing and administering amphotericin B. Am J Hosp Pharm 1992; 49:1156-1164.
41. Freifeld AG. The antimicrobial armamentarium. Hematol Oncol Clin North Am 1993; 7:813-839.
42. Branch RA. Prevention of amphotericin B-induced renal impairment-A review on the use of sodium supplementation. Arch Int Med 1988; 148:2389-2394.
43. Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity: standard of care? West J Med 1995; 162:313-317.
44. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6:154-164.
45. Brown P, Lundberg WB. Amphotericin B IV Management Protocol. New Haven, CT: Hospital of Saint Raphael; 1993.
46. Holtzclaw BJ, Rutledge DN. Use of amphotericin B in immunosuppressed patients with cancer: part two, pharmacodynamics and nursing implications. Oncol Nurs Forum 1990; 17:737-741.
47. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for adverse events related to infusions of amphotericin B. Clin Infect Dis 1995; 20:755-761.
48. Hart LL, Middleton RK, McQueen KD. DIAS rounds: drug information analysis service. Drug Intelligence Clin Pharm: Ann Pharmacother 1990; 24:597-598.
49. Gales MA, Gales BJ. Rapid infusions of amphotericin B in dextrose. Ann Pharmacother 1995; 29:523-529.